Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Trifluridine and Tipiracil in Colorectal Cancer
NCT03974594Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trifluridine + tipiracil in colorectal cancer (CRC) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time at 3 days, Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration at 3 days and 1 more. Started May 2019; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03974594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974594.